For this, we applied monoclonal antibodies to block IFNγ activity during NK‐cell–melanoma cell co‐culture (see Fig. 4A; approach 1) or by adding recombinant IFNγ to melanoma cells instead of using primary NK‐cells as a source (Fig. 4A; approach 2). Here, IFNG is linked to melanoma.